The question of ozempic vs mounjaro is no longer theoretical. Since the SURMOUNT-5 trial published its results in May 2025, we have direct head-to-head clinical data comparing these two medications for the first time. The answer is nuanced: one drug produces more weight loss, while the other may offer specific advantages that make it the better choice for certain patients.
This guide covers what the evidence actually shows, including what gets left out of most comparisons.
Understanding the Name Confusion First
Before comparing these drugs, it helps to understand that four brand names refer to just two medications.
Semaglutide is sold as Ozempic when prescribed for type 2 diabetes, and as Wegovy when prescribed specifically for obesity at its higher approved dose. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for obesity management.
When most people search for ozempic vs mounjaro, they are usually asking about the weight loss comparison, which is the Wegovy vs Zepbound question. The diabetes-approved versions are the same underlying drugs, just with different approved dose ceilings. This guide addresses both contexts.
How Ozempic and Mounjaro Work Differently
The key pharmacological difference is the number of receptors each drug activates.
Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone, which reduces appetite, slows gastric emptying, and stimulates insulin release after meals. This single-receptor approach produces meaningful weight loss and blood sugar improvement.
Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 pathway and the GIP (glucose-dependent insulinotropic peptide) pathway simultaneously. GIP receptors play a role in fat storage, insulin sensitivity, and energy regulation. The dual activation appears to amplify the metabolic effects beyond what either receptor alone can produce.
This mechanism difference is the primary driver of Mounjaro’s superior weight loss outcomes in clinical trials.
Ozempic vs Mounjaro: Side-by-Side Comparison
| Feature | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| FDA-approved uses | Type 2 diabetes, cardiovascular risk, kidney disease | Type 2 diabetes (adults and ages 10+) |
| Weight loss version | Wegovy (2.4 mg) | Zepbound (up to 15 mg) |
| Average weight loss (SURMOUNT-5) | 13.7% of body weight | 20.2% of body weight |
| Administration | Weekly injection or daily oral tablet | Weekly injection only |
| Lean mass preservation | Better preserved at 12 months | More total weight lost |
| Estimated monthly cost | $900 to $1,000 | $1,000 to $1,100 |
| Available as generic | No | No |
What the SURMOUNT-5 Trial Found
SURMOUNT-5 was a Phase IIIb randomized controlled trial, the first to directly compare tirzepatide and semaglutide in the same study population. Results were published in May 2025.
The trial enrolled 751 adults with obesity but without type 2 diabetes at 32 sites across the United States. Participants received either the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) by weekly injection for 72 weeks.
Tirzepatide produced 20.2% average weight loss from baseline. Semaglutide produced 13.7%. The difference of approximately 6.5 percentage points was statistically significant and clinically meaningful. Tirzepatide participants were also more likely to achieve 20% or greater weight loss, and showed greater reductions in waist circumference.
Rates of serious adverse events were comparable between the two groups. Both caused similar gastrointestinal side effects, primarily nausea, vomiting, and diarrhea, with no significant difference in safety signals.
Weight Loss Results: A Broader View
SURMOUNT-5 provides the clearest comparison, but earlier data support the same direction. A 2025 systematic review and meta-analysis published in PMC analyzed results across multiple clinical trials and real-world datasets.
The meta-analysis found tirzepatide consistently produced greater weight loss than semaglutide across studies, with the advantage appearing more pronounced at higher doses and over longer durations. This aligns with the dual-receptor mechanism: the GIP pathway adds metabolic signal that semaglutide alone cannot replicate.
For most patients whose primary goal is maximum weight loss, tirzepatide (Mounjaro/Zepbound) produces better outcomes.
The Muscle Mass Trade-off
One finding that rarely gets adequate attention in ozempic vs mounjaro comparisons is the difference in lean body mass preservation.
Because tirzepatide produces more aggressive total weight loss, it also produces more lean tissue loss in absolute terms. Comparative analyses suggest that people on tirzepatide lose approximately 2% more lean body mass at 12 months than those on semaglutide at comparable time points.
For patients whose goals extend beyond the scale, this matters. Lean muscle mass supports metabolic rate, functional strength, bone density, and longevity. Losing more of it during weight loss is a meaningful trade-off, particularly for adults over 50, athletes, and anyone focused on body composition rather than just body weight.
The SEMALEAN study specifically examined semaglutide’s effect on fat mass, lean mass, and muscle function, finding that semaglutide-driven weight loss could be structured to preserve functional muscle capacity with appropriate nutritional and exercise support.
Both medications benefit significantly from resistance training and adequate protein intake. However, the data suggests this intervention is especially important for patients on tirzepatide, given its more pronounced lean mass reduction.
Side Effects: How They Compare
The side effect profiles of Ozempic and Mounjaro are broadly similar. Both belong to the GLP-1 class and share the same core side effect pattern: gastrointestinal symptoms that are most common during dose escalation and typically improve over time.
Most common with both medications:
- Nausea (most frequent, especially during the first 4 to 8 weeks)
- Vomiting
- Diarrhea
- Constipation
- Reduced appetite and thirst
Serious but rare risks shared by both:
- Pancreatitis
- Gallbladder disease
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Thyroid C-cell tumor risk (boxed warning on both labels; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2)
SURMOUNT-5 found no statistically significant difference in serious adverse event rates between the two drugs. Patients who cannot tolerate semaglutide’s gastrointestinal effects often find tirzepatide similarly challenging, and vice versa. Side effect experience is highly individual.
Ozempic vs Mounjaro Cost
Both medications are expensive without insurance coverage. As of mid-2026, the estimated retail price for Ozempic is approximately $900 to $1,000 per month, while Mounjaro runs approximately $1,000 to $1,100 per month. Neither is available as a generic.
Insurance coverage follows the FDA-approved indication. If you are prescribed the diabetes-branded versions (Ozempic, Mounjaro) for type 2 diabetes, coverage is generally available through most plans. If prescribed for obesity alone using the weight-loss-branded versions (Wegovy, Zepbound), coverage varies significantly by plan and employer.
Novo Nordisk (the maker of Ozempic) and Eli Lilly (the maker of Mounjaro) each offer patient savings programs that can reduce monthly costs substantially for commercially insured patients who qualify. Compounded versions of both drugs also remain available through some specialty pharmacies, though regulatory guidance on compounded semaglutide and tirzepatide has shifted in recent years and should be discussed with a healthcare provider.
Which Drug Is Right for You?
The evidence supports tirzepatide (Mounjaro/Zepbound) as the more effective choice for maximum weight loss. But several factors may make semaglutide (Ozempic/Wegovy) the better fit for specific patients.
Ozempic/Wegovy may be preferable if:
- You have established cardiovascular disease and want the SELECT trial-backed CV risk reduction
- You have chronic kidney disease (Ozempic has an FDA approval for kidney disease progression)
- Preserving lean muscle mass is a high priority for you
- You prefer or need an oral medication option (Rybelsus, the oral semaglutide, is available; no oral tirzepatide exists as of 2026)
- Insurance coverage or cost makes semaglutide more accessible
Mounjaro/Zepbound may be preferable if:
- Your primary goal is maximum weight loss
- You have not achieved sufficient results on semaglutide
- You have type 2 diabetes needing superior blood sugar control
- Muscle mass is a secondary concern and you plan to offset lean mass loss with exercise and protein
No drug comparison substitutes for a physician-guided decision. These factors interact with individual health history in ways that a comparison article cannot fully account for.
Can You Switch Between Them?
Switching from one to the other is clinically common. The typical approach is to stop the current medication and begin the new one the following week at the lowest introductory dose, then escalate according to that drug’s titration schedule.
Dose equivalency between the two drugs is not direct. You cannot simply translate your current semaglutide dose into a tirzepatide dose and expect the same effect or tolerance. Starting at the lowest available dose and titrating gradually reduces the risk of side effects during the transition.
Patients who switch from Ozempic to Mounjaro typically do so because Mounjaro’s weight loss advantage is a priority, or because they reached a plateau on semaglutide. Switching from Mounjaro to Ozempic is less common but occurs when cardiovascular indications, lean mass concerns, or insurance changes drive the decision.
Consult your prescribing physician before making any changes. Both transitions involve clinical judgment about dose timing, monitoring, and goal alignment.